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compounds that circumvent a block of 
the mitochondrial apoptotic signaling 
pathway? Fecker et al. (2006) examined 
a limited panel of metastatic tumors 
and, surprisingly, found not only loss 
of proapoptotic Bax, Bak, and Bok, but 
also loss of antiapoptotic Bcl-2 fam-
ily members such as Bcl-2 and Mcl-1. 
Why are antiapoptotic molecules such 
as Bcl-2 and Mcl-1 downregulated in 
metastatic melanoma? Although at first 
glance counterintuitive, these findings 
might be in line with a recent report that 
antiapoptotic Bcl-2 family members are 
immunogenic (Andersen et al., 2005). 
Thus downregulation of these molecules 
during tumor progression might be 
needed to overcome tumor immune sur-
veillance, and these tumor cells might 
survive only if they also lose expression 
of the proapoptotic Bax and Bak. Of 
note, small molecules that inhibit the 
BH3-binding groove are highly promis-
ing in preclinical testing for solid-can-
cer therapy (Oltersdorf et al., 2005). 
However, the data of Fecker et al. (2006) 
hint at the possibility that melanoma 
treatment would have to circumvent loss 
of Bax and Bak to overcome apoptosis 
resistance. Obviously the studies will 
have to be extended to larger panels of 
tumors and metastases, most interest-
ingly in samples of primary and metas-
tasized tumors in the same individuals. 
Because sentinel lymph node biopsy 
is now widely performed for primary 
melanoma (Ulrich et al., 2004), this infor-
mation may soon be available and might 
confirm whether early loss of Bax or Bak 
is indeed relevant for prognosis at the 
time of primary diagnosis of melanoma. 
Intriguingly, it can be envisioned that, 
beyond being classified solely by histo-
pathological analysis, melanomas may 
be best described on the basis of their 
inactivation profile of distinct signaling 
pathways, and these molecular patterns 
might reflect distinct oncogenic profiles 
(Curtin et al., 2005). In this context, Bax 
and Bak may help us “back to  the future” 
of primary melanoma prognosis.
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Genomic Instability and Tumor Stem 
Cells
James M. Grichnik1
Wang et al. point to the existance of a common progenitor tumor stem cell that 
gives rise to genomically unstable progeny in malignant melanoma. Although it 
is not known what creates this genomic instability, given the presence of testis 
antigens in melanoma, it is tempting to speculate that it is caused by a collision 
of meiotic and mitotic pathways.
Journal of Investigative Dermatology (2006) 126, 1214–1216. doi:10.1038/sj.jid.5700240
Genomic instability is one of the hall-
marks of cancer. Curiously, it is not 
clear whether genomic instability is 
causative or just a ramification of the 
malignant process — or both. In this 
issue, Wang et al. (2006) present data 
from a melanoma patient who experi-
enced apparent complete remissions 
and subsequent recurrences over a 12-
year period. The findings of their study 
point to the existence of a common 
progenitor tumor cell that gives rise to 
genomically unstable progeny.
Wang et al. (2006) karyotyped cells 
from successive melanoma recur-
rences in their patient. The karyo-
1Division of Dermatology, Department of Medicine, Duke University Medical Center, Durham, North 
Carolina, USA
Correspondence: Dr. James M. Grichnik, Box 3135, Division of Dermatology, Department of Medicine, 
Duke University Medical Center, Durham, North Carolina 27710, USA. E-mail: grich001@mc.duke.edu
COMMENTARY
 www.jidonline.org 1215
types revealed some similar patterns 
of chromosomal aberrations, but the 
aberrations for each recurrence were 
sufficiently different that they could not 
be accounted for by a sequential pro-
cess. In fact, even the cells karyotyped 
from the same culture revealed differ-
ences suggesting ongoing chromosom-
al instability within the cell population 
isolated from each metastasis. The fact 
that the subsequent recurrences did not 
build on the genomic alterations found 
in the earlier recurrences suggested 
that there must have been progenitor 
cells responsible for the metastases that 
were more genomically stable than the 
cells karyotyped.
A 1-bp mutation, a TCT-to-TTT 
mutation resulting in a Ser37-to-Phe37 
substitution in the β-catenin gene, was 
present in all the metastatic cells tested 
(Wang et al., 2006). The presence of 
this single-base mutation in all the cells 
suggested that the mutation was pres-
ent in the common progenitor tumor 
cell giving rise to the recurrences. The 
role of β-catenin in self-renewal of stem 
cells makes this a particularly interest-
ing finding.
Our understanding of the role of 
stem cells in cancer development is 
evolving quickly. In metastatic mela-
noma, a sub-population of cells with 
stem-cell-like features has been noted 
(Grichnik et al., 2006). It is proposed 
that these tumor stem cells give rise 
to transiently amplifying tumor cells 
that make up the majority of the tumor 
bulk before terminally differentiat-
ing. Theoretically, as long as a nidus 
of tumor stem cells are present, the 
tumor can continue to expand, and 
if the tumor stem cells circulate, they 
can give rise to distant metastases. 
Combining the findings of Wang et 
al. (2006) with the tumor stem cell 
concept, a model can be developed. 
The patient’s tumor stem cells would 
be expected to carry β-catenin (and 
potentially other relevant mutations) 
but otherwise would still be relative-
ly genomically intact and retain the 
capacity to metastasize. The transient-
ly amplifying cell progeny from the 
tumor stem cells would be genomi-
cally unstable, creating the majority of 
cells in the tumor bulk, but would be 
metastatically incompetent.
Although our understanding of 
tumor stem cell biology is still in its 
infancy, the tumor stem cell model is 
attractive because of its integration of 
broken, but natural, stem-cell develop-
mental pathways. With this model, it is 
no longer necessary to require mature 
cells to “dedifferentiate” into less dif-
ferentiated cancer cells. It is no longer 
necessary for cells to acquire meta-
static capabilities, as “metastasis” may 
simply be the result of tumor stem cells 
attempting to follow normal circulatory 
and tissue-regenerative stem-cell pro-
cesses. But what about genomic insta-
bility? Is there a normal developmental 
mechanism that might account for this 
process? Currently the literature would 
point toward ineffective DNA repair 
mechanisms (Charames and Bapat, 
2003) or telomere dysfunction (Gilley 
et al., 2005) coupled with the inability 
to stop cells from progressing through 
the cell cycle. Certainly these processes 
could account for increased genomic 
instability downstream from the tumor 
stem cell due to the expected telo-
mere shortening and increased prolif-
erative rates that stress the DNA repair 
machinery in the transiently amplifying 
cells. However, there is another pos-
sible source of genetic instability, one 
designed for the express purpose of 
mixing up the genome with each gen-
eration: meiosis.
Meiosis is an evolved form of mito-
sis that drives genetic diversity by (1) 
producing chiasma (chromosomal 
crossing-over points) between heter-
ologous chromosomes and (2) seg-
regating homologous chromosomes 
“glued” together in meiosis I. What if 
a tumor cell were unsure whether it 
was to undergo mitosis or meiosis and 
therefore did a little of each? Crossing 
over might not be resolved by the 
time chromosomes were pulled apart, 
resulting in chromosomal breakage. 
Some chromosomes might be held 
together as if in meiosis I, resulting in 
duplication in some cells and chro-
mosomal loss in others. In support of 
this hypothesis, it is important to note 
that testis antigens are often expressed 
in melanoma (Simpson et al., 2005). 
Further, some of these antigens have 
now been shown to be specific for 
meiosis (Chen et al., 2005; Tureci et 
al., 1998). It is possible that the tumor 
stem cells produce transiently ampli-
fying cells that are not entirely sure 
whether they are somatic cells or germ 
cells. A little bit of meiosis mixed in 
with mitosis would certainly be suffi-
cient to drive genomic instability.
Whether it is meiosis, defective DNA 
repair, and/or telomere dysfunction, it 
is of interest that the genomic instability 
in successive recurrences in the study 
of Wang et al. (2006) shared several 
similarities in chromosomal losses and 
gains. This suggests that there is some-
thing about the organization of the 
genome that reproducibly makes cer-
tain regions more unstable. Bastian et 
al. (2000) have noted that certain mela-
nomas tend to have specific genomic 
instability patterns. Thus it is reason-
able to assume that this is a consistent 
phenomenon in melanoma cells. It is 
not clear what makes one part of the 
genome more stable than another, but 
future efforts may find that genomic 
stability configurations are dependent 
on nuclear organization patterns that 
may be driven inherently by the type of 
mutation(s) present in the tumor stem 
cell, the type of stem cell involved, or 
local environmental influences.
In summary, the findings of Wang 
et al. (2006) support an emerging new 
cancer model — one based not on 
the aggressive acquisition of malig-
nant abilities of mature tissue cells, 
but on inherently normal stem-cell 
developmental pathways with broken 
regulatory mechanisms. It is still too 
early to know whether the tumor stem 
cell model will hold up, but its future 
looks promising and it is likely to have 
major ramifications for the understand-
ing of this disease process as well as to 
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within the cell 
population isolated from 
each metastasis.
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enhance our ability to diagnose and 
treat malignant tumors.
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More than One Gene Involved in 
Monilethrix: Intracellular but also 
Extracellular Players
Jürgen Schweizer1
Monilethrix, an autosomal dominant human hair disorder, is caused by muta-
tions in three type II hair cortex keratins. Rare cases of the disease with non-
vertical transmission have now been found to overlap with localized autosomal 
recessive hypotrichosis. The underlying gene, desmoglein 4 (DSG4), belongs to 
the desmosomal cadherin superfamily and is also expressed in the cortex of the 
hair follicle.
Journal of Investigative Dermatology (2006) 126, 1216–1220. doi:10.1038/sj.jid.5700266
In 1997 it was demonstrated that the 
principle of a causal relationship 
between mutated epithelial keratins 
and human genodermatoses holds 
true also for mutated hair keratins and 
hereditary hair disorders. The respec-
tive disease, monilethrix (from the Latin 
for “necklace” and the Greek for “hair”; 
OMIM #158000 and #252200), is con-
sidered an autosomal dominant condi-
tion with high penetrance but variable 
expression and belongs to a variety of 
congenital hair diseases whose hall-
mark is an unusually deformed hair 
shaft. Monilethrix was so named for the 
beaded appearance of affected hairs. 
These exhibit elliptical nodes of nor-
mal thickness that are regularly sepa-
rated by dystrophic constrictions. The 
internodes possess a high propensity 
to break, leading to alopecia; that is, 
short stubble hair associated with fol-
licular keratosis and perifollicular ery-
thema. In the mildest form, the disease 
involves only the occiput and the nape 
of the neck, but in its severe form, the 
entire scalp, secondary hairs, eyebrows, 
and eyelashes may also be involved. 
In addition, subtle nail defects have 
been reported. Occasionally, regrowth 
of apparently normal hair may occur 
at the time of puberty or during preg-
nancy. Ultrastructurally, vacuolation 
and alterations in the fibrillar struc-
tures of lower cortex cells have been 
described (for a review, see Langbein 
and Schweizer, 2005).
The three hair keratin genes that 
proved to be causal for monilethrix 
encode the type II hair keratins Hb1, 
Hb3, and Hb6, which share a com-
pletely identical α-helical rod domain 
and, in line with the ultrastructurally 
observed disease symptoms, are all 
expressed in the hair cortex. Besides 
sporadic mutations in the 1A helix 
initiation motif, two non-conservative 
mutational hot spots in the 2B helix 
termination motif, Glu413Lys and 
Glu402Lys, were observed, Glu413Lys 
being most frequent in Hb6 and 
Glu402Lys being more abundant in 
Hb1 (Langbein and Schweizer, 2005). 
Curiously enough, up to now, only 
one monilethrix family exhibiting the 
equivalent of the Glu402Lys mutation 
in Hb3 (Glu407Lys) has been reported 
(van Steensel et al., 2005). The numer-
ous monilethrix families that have been 
investigated since 1997 indicate that 
there is no genotype–phenotype cor-
relation for the disease. One impressive 
example of the variability of the pheno-
type was noted in a pedigree in which, 
of three carriers of the Hb1 Glu402Lys 
mutation, two children exhibited bead-
ed hairs that were visible either to the 
naked eye or upon electron microscop-
ic inspection. In contrast, their moth-
ers’ hairs appeared completely healthy, 
but the moniliform phenotype could 
easily be demonstrated in archival 
hairs removed from the mother during 
early childhood. On the other hand, a 
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